ECSP972115A - SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS - Google Patents
SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORSInfo
- Publication number
- ECSP972115A ECSP972115A ECSP972115A ECSP972115A EC SP972115 A ECSP972115 A EC SP972115A EC SP972115 A ECSP972115 A EC SP972115A EC SP972115 A ECSP972115 A EC SP972115A
- Authority
- EC
- Ecuador
- Prior art keywords
- disorders
- present
- graph
- carbons
- alkyl
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención presenta composiciones farmacéuticas y métodos para tratar ciertos trastornos, que comprenden administrar una cantidad de un compuesto o composición de la presente invención que sea eficaz para inhibir la actividad de por lo menos una metaloproteasa de matriz, que da como resultado la obtención del efecto deseado. Los compuestos de la presente invención tiene la fórmula generalizada (gráfico), donde y es 0,2 ó 3, r es 0-6, Z es (CH2)7-O(CH2)e-C6H4-(CH2)r o donde e es 0-1 y f es 1-6; R15 es -H, -CI-=Me o (gráfico), donde n es 0-4, R17 es -C2H5,-arilo o -bencilo y R16 es (gráfico), donde t es 0-1, x es 0-4 y R4 es uno de los siguientes; haluro, alquilo de 1 a 6 carbonos, OR, NR2, NO2, (R=H o alquilo de 1 a 6 carbonos). Estos compuestos son útiles para inhibir las metaloproteasas de matriz y, por lo tanto, para combatir los trastornos a los cuales contribuyen las MMP, tales como la osteoartritis, la artritis reumatoidea, la artritis séptica, las enfermedades periodontales, las úlceras de córnea, la proteinuria, la enfermedad de aneurisma aórtico, la epidermolisis vesicular distrófica, los trastornos que producen respuestas inflamatorias, las osterpenias en las que media la actividad de MMP, la enfermedad de la articulación temporomandibular, las enfermedades desmielinizantes del sistema nervioso, las metástasis de tumores o la pérdida degenerativa de cartilago posterior a la lesión articular traumática, y la trombosis coronaria a partir de la ruptura de placa ateroesclerótica. La presente invención se relaciona asi mismo con composiciones farmacéuticas y métodos para tratar dichos trastornos.The present invention features pharmaceutical compositions and methods of treating certain disorders, which comprise administering an amount of a compound or composition of the present invention that is effective in inhibiting the activity of at least one matrix metalloprotease, resulting in obtaining the desired effect. The compounds of the present invention have the generalized formula (graph), where y is 0.2 or 3, r is 0-6, Z is (CH2) 7-O (CH2) e-C6H4- (CH2) ro where e is 0-1 and f is 1-6; R15 is -H, -CI- = Me or (graph), where n is 0-4, R17 is -C2H5, -aryl or -benzyl, and R16 is (graph), where t is 0-1, x is 0- 4 and R4 is one of the following; halide, alkyl of 1 to 6 carbons, OR, NR2, NO2, (R = H or alkyl of 1 to 6 carbons). These compounds are useful for inhibiting matrix metalloproteases and, therefore, for combating disorders to which MMPs contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal diseases, corneal ulcers, proteinuria, aortic aneurysm disease, dystrophic vesicular epidermolysis, disorders that produce inflammatory responses, osterpenias in which MMP activity mediates, temporomandibular joint disease, demyelinating diseases of the nervous system, tumor metastasis, or degenerative loss of cartilage after traumatic joint injury, and coronary thrombosis from atherosclerotic plaque rupture. The present invention likewise relates to pharmaceutical compositions and methods of treating such disorders.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ECSP972115 ECSP972115A (en) | 1997-05-12 | 1997-05-12 | SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ECSP972115 ECSP972115A (en) | 1997-05-12 | 1997-05-12 | SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP972115A true ECSP972115A (en) | 1998-04-24 |
Family
ID=42042946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP972115 ECSP972115A (en) | 1997-05-12 | 1997-05-12 | SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS |
Country Status (1)
Country | Link |
---|---|
EC (1) | ECSP972115A (en) |
-
1997
- 1997-05-12 EC ECSP972115 patent/ECSP972115A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE89263T1 (en) | NAPHTHALINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
ES2036190T3 (en) | NEW DERIVATIVES OF DIPHOSPHONIC ACIDS, PROCEDURE FOR THE PREPARATION AND MEDICINES CONTAINED IN THESE COMPOUNDS. | |
ES2056810T3 (en) | DERIVATIVES OF PHOSPHINIC ACID. | |
KR20070031274A (en) | Hyaluronic acid derivative and drug containing the same | |
ES2014220B3 (en) | NEW DERIVATIVES OF DIPHOSPHONIC ACID, PROCEDURE FOR ITS PREPARATION AND MEDICINES CONTAINED IN THESE COMPOUNDS. | |
AR007098A1 (en) | MATRIX METALOPROTEASE INHIBITORS, COMPOSITIONS UNDERSTANDING THEM, AND USE OF THEM TO PREPARE PHARMACEUTICAL COMPOSITIONS | |
ATE203409T1 (en) | PHOSPHONOCARBOXYLATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | |
ES2078507T3 (en) | MEDICINES AND DERIVATIVES OF SULFONANILIDE. | |
AR007096A1 (en) | MATRIX METALOPROTEASE INHIBITOR COMPOUND METHOD FOR INHIBITING ITS ACTIVITY, A CONTAINING COMPOSITION AND USE OF SUCH COMPOUNDS TO PREPARE PHARMACEUTICAL COMPOSITIONS | |
SK58399A3 (en) | Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors | |
AR007100A1 (en) | INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED PHENYLALKYL COMPOUNDS AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT. | |
BR0008778A (en) | Prostaglandin analogs selective for unsaturated fpc16 | |
AR007097A1 (en) | BIARYLACETHYLENE MATRIX METALOPROTEASE INHIBITORS, A COMPOSITION THAT HAS MATRIX METALOPROTEASE INHIBITING AND THE USE OF SUCH BIARYLACETILENE IN THE MANUFACTURE OF A MEDICINAL PRODUCT. | |
ECSP972115A (en) | SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS | |
DE69600272D1 (en) | Quinoline-4-carbonylguanidine derivatives, processes for their preparation and pharmaceutical compositions containing them | |
ATE169635T1 (en) | THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH GLUTATHIONE DEFICIENCY, PRODUCTION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINED THEREOF | |
ECSP972111A (en) | MATRIX METALOPROTEINASES INHIBITORS BY ACIDS 2- (AROILALQUIL) -4 BIARIL-4- OXOBUTIRICOS | |
ECSP972112A (en) | INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED FENETILE COMPOUNDS | |
ECSP972113A (en) | INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED BIARILOXOBUTIRIC ACIDS | |
ECSP972114A (en) | BIARYLACETYLENE AS INHIBITORS OF MATRIX METALOPROTEASE | |
PA8429601A1 (en) | INHIBITION OF MATRIX METALOPROTEINASES BY ACIDS 2- (W-AROILALQUIL) -4-BIARIL-4-OXOBUTIRICOS. | |
AU665968B2 (en) | New non ionic iodized agents for X-ray contrasting, method for preparing them and galenical compositions containing them | |
DE69401327T2 (en) | NON-IONIC IODINE DIMERS AS AN X-RAY CONTRAST, METHOD FOR THE PRODUCTION THEREOF AND GALENIC COMPOSITIONS CONTAINING THEM | |
TH12333B (en) | Inhibition of matrix methalloprotein by substitutedphenethyl compounds. | |
TH35864A (en) | Inhibition of matrix methalloprotein by substitutedphenethyl compounds. |